#hypoxia key companies | Explore Tumblr posts and blogs

poppadom0912 · 7 months ago

Text

Holding On Sequel

Warnings: Mentions of guns, injuries, hospitals, angst

Summary: Recovery from the worst night of the Halstead's lives seems impossible.

A/N: Wrote this randomly when I remembered receiving several comments wanting a part two and after much deliberation on the plot, this is what I came up with. I'm not a medical professional, everything mentioned is all from google. Please enjoy the ending of this as there won't be a third part to what was supposed to be a oneshot ;)

*****

Things were never the same following the night of the accident.

Jay and Will found themselves at your beside for however long they were permitted to. During his shifts, at his breaks and whenever he found time, Will found himself in your room watching your coma ridden self and Jay would always call and text for updates, every other minute out of work spent in the hospital.

The surgery had been a success, no one ever doubted it when Connor took charge, but it was the aftermath that had gone downhill.

Cerebral hypoxia caused from the severe blood loss and haemorrhaging, causing damage to your brain, the extent of damage which even Abrams struggled to determine as long as you remained unconscious.

The coma lasted for such a long period of time that Abrams was hesitant in keeping your life support machine on.

Jay had a tiny bit of a go at the man for suggesting such a thing, Will attempting to hold him back from doing anything brash.

So Abrams took a step back for another week and the next time, Charles approached the brothers instead. His ever so gentle and understanding voice with his soft eyes causing them to crumble.

It seemed that everyone had come to a collective conclusion, tonight when both their shifts were over, they'd say their last messages and goodbyes before Abrams would pull the plug.

That day, like clockwork, Will took his lunch break too eat his sandwich at your side, talking and telling you everything and anything like he always did. Eventually, someone would always join him for moral support or for some company, either or, today it being April who also was on her break.

As Will combed his fingers through your knotted and greasy hair, their was a sudden spike in your heart monitor causing his fingers to abruptly pull at a tough knot, his own heart thundering, head snapping up to look at the machine in question.

Both doctor and nurse sat in silence, staring at the machine with sharp eyes, ready for any other fluctuations.

A higher pitched beep went off two minutes later, Will choking out a breathy laugh at the moment he believed was never going to come.

Struggling to formulate any thoughts, he turned back to look at you, his eyes softening paired with watery smile.

"it's okay Y/N." He swallowed harshly, barely listening to April calling for Abrams as the heart monitor continued to go off.

"Take as much time as you need."

*****

"Hey, you all finished?

Jay appeared out of nowhere, walking towards you with his keys in hand very casually like he hadn't just scared the living hell out of you.

"Yeah, almost. I just have to mark these last few questions and then we can go home." You said, gesturing to the test papers in front of you on your desk.

Jay hummed, perching himself on the tables that you forbid your kids from sitting on where he sat whistling till you were done.

Around fifteen minutes later, you were done. All your things were now back in their shelves and drawers, your bag packed as your announced you could leave now.

Jumping off the table, Jay rounded the desk and took hold of the wheelchair handles, pushing you out of the classroom, pausing so you could lock the door behind you.

This was your new norm.

Two months post waking up from your coma and, you were thriving as much as you could adjusting to this new lifestyle.

Only two weeks ago were you able to get back to work, spending all your time in and out of rehab and physical therapy, the latter of which you still attended.

The Cerebral Hypoxia affected your ability to speak and walk, the former which was fixed within a month of rehab but the latter...

Well, you were in a wheelchair for a reason.

To cater to such a sudden change in lifestyle, both Will and Jay took their turns in helping, acting as carers of sorts especially in the beginning of your recovery.

Their shared efforts leading to your current living situation - the three of you living together in a completely new place that had wheelchair accessibility that you were able to afford combining three salaries.

Even now, there were still some things that you hadn't become accustomed to such as: wheeling yourself everywhere, relying on others for small tasks like laundry and the sympathy from the entire world.

You would never get used to the stares you continued to receive at school from the children.

"Will get's off in a hour, he's asking about takeout." Jay said, cutting you off from your train of thought as you reminisced on your current recovery.

"Our usual Chinese place is good for me." You said, watching as he typed something into his phone, most likely texting Will your words. "I'm really craving their duck."

"Perfect." He mumbled, turning his phone off as he started the car to drive home.

It took a very long time to work out how to get you and the wheelchair both in and out of the car but after much trial and error and eventually help from your physical therapist, it all worked out.

Will and Jay were changed men after you woke up from the coma. They were, if even possible, more protective of you than before to a point where the line between overprotective and overbearing was extremely thin.

But all three of you had to learn and adjust, making mistakes and sacrifices necessary in making this recovery and new lifestyle work.

You wished you could turn back time and change things, going back to that fateful night where you could change what you did.

Thinking back to it now, you would've been smarter, used some common sense and put your card some place sensible, maybe walk faster to the station instead of pausing in the middle of a dark street nowhere near the main road or civilisation.

But alas, no matter the regret, it was all in the past now, as your therapist said, dwelling on it won't change the present.

All you could do is what was in your control which currently consisted on focusing on your physio to try and get your legs to improve even somewhat, try to enjoy being coddled by your older brothers like you were all kids again and continue to teach the children who never failed to make you feel better.

While you were well into the recovery process, there was still much progress to be made and in an ideal world, by the end of it all, you'd be back to normal and stable on your own two feet. A life where everyone could go back to their lives, Will and Jay being allowed to live their lives independently without having to help you get into the shower or bed.

For now though, all you had to do was focus on yourself, taking small baby steps to try and get back to being you again.

"For fucks sake- Will forgot the prawn crackers!"

With these morons at your side, being you was easier than ever.

#one chicago x reader #one chicago imagine #one chicago fic #chicago med #one chicago fanfiction #chicago pd #jay halstead x reader #will halstead x reader #halstead sister #halstead brothers #will halstead x sister!reader #jay halstead x sister!reader

136 notes · View notes

delveinsight12 · 2 months ago

Text

Hypoxia Market Growth Anticipated by 2032

The Hypoxia market is poised for remarkable growth over the forecast period, driven by advancements in therapeutic solutions and increased research and development (R&D) activities. According to DelveInsight’s comprehensive report, titled “Hypoxia Market Insights, Epidemiology, and Market Forecast 2032,” the market is set to expand significantly, with key players like ReAlta Life Sciences and Biogen leading the charge.

Download our sample report @ https://www.delveinsight.com/report-store/hypoxia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr

Hypoxia Market Dynamics and Key Drivers

The market landscape of Hypoxia, a medical condition characterized by reduced oxygen levels in tissues, is expected to flourish between 2019 and 2032. The report examines treatment practices, emerging therapies, and the anticipated trajectory of the Hypoxia market size across the seven major markets (7MM): the United States, EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan.

Extensive R&D Activities:

The robust pipeline of therapies targeting Hypoxia reflects increasing investments by academic institutions and pharmaceutical companies. ReAlta Life Sciences and Biogen, among others, are advancing innovative therapies aimed at mitigating symptoms and addressing the underlying causes of Hypoxia.

Key drugs in development, such as RLS-0071 and TMS-007, are expected to drive growth significantly during the forecast period (2023–2032).

Rising Awareness and Market Expansion:

Enhanced disease awareness, coupled with improved diagnostic methods, is facilitating early detection and treatment. This trend is projected to bolster market growth.

Increasing healthcare expenditure worldwide further supports the development and accessibility of advanced treatments.

Learn more about hypoxia therapeutic advancements @ https://www.delveinsight.com/sample-request/hypoxia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr

Hypoxia Therapeutic Advancements

Therapeutic innovation is at the heart of Hypoxia market growth. Emerging treatments target not only symptom management but also preventive measures against vascular brain disorders, which are critical to Hypoxia-related conditions. Clinical advancements include:

Management Strategies:

Maintaining patent airways and increasing oxygen content in inspired air.

Physical, occupational, and speech therapies to restore function in cases of cerebral hypoxia.

Use of blood thinners, antibiotics, and surgical interventions to address underlying causes of Hypoxia.

Adoption of assistive devices like wheelchairs, along with psychotherapy and mechanical ventilation for severe cases.

Pipeline Developments:

Key therapies such as RLS-0071 and TMS-007 are showing promise in clinical trials, reflecting potential to fill current treatment gaps.

Biogen is among the frontrunners in developing targeted therapies for hypoxic stroke, a critical condition with substantial clinical and societal impacts.

Hypoxia Epidemiology and Market Segmentation

The prevalence of Hypoxia spans various demographic and clinical dimensions. Notable statistics include:

Global Incidence Rates:

Approximately 50 cases of hypoxic brain injury per 100,000 population annually.

Survival-to-discharge rates of around 8% in the United States, translating to over 10,000 patients per year.

Nearly two million stroke incidents reported annually in the United States and the European Union, according to Biogen (2022).

Segmentation Metrics:

Total prevalence by severity, age, and gender.

Diagnosed cases and type-specific prevalence across the 7MM.

Download our sample pages @ https://www.delveinsight.com/report-store/hypoxia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr

Competitive Landscape

Key players in the Hypoxia market are leveraging innovative approaches to secure market share. Companies like ReAlta Life Sciences and Biogen are setting benchmarks with therapies targeting unmet needs. Strategic collaborations, portfolio expansions, and regulatory approvals are pivotal in defining the competitive landscape.

Opportunities and Challenges

Opportunities:

Addressing unmet needs by developing therapies for conditions with limited existing treatments.

Leveraging advanced technologies and partnerships to accelerate drug development.

Educating healthcare professionals and patients to promote early diagnosis and intervention.

Challenges:

High costs associated with R&D and therapy development.

Regulatory hurdles and the need for rigorous clinical validation.

Strategic Insights for Stakeholders

The Hypoxia market report underscores actionable strategies for stakeholders:

Market Positioning:

Identifying gaps in existing treatment paradigms and aligning product development to fill these voids.

Leveraging epidemiological insights to guide strategic decisions.

Roadmap to Success:

Establishing short-term and long-term objectives for market entry and expansion.

Aligning R&D investments with emerging trends and future projections.

Request for a detailed sample pages on hypoxia market @ https://www.delveinsight.com/sample-request/hypoxia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr

Conclusion

The Hypoxia market is on a transformative trajectory, fueled by advancements in therapeutic interventions and a deeper understanding of the disease. Stakeholders, including pharmaceutical companies, healthcare professionals, and policymakers, are well-positioned to harness this growth potential. By addressing unmet needs and optimizing treatment pathways, the industry can significantly improve patient outcomes while driving market success.

For an in-depth analysis of the Hypoxia market, including key players, emerging therapies, and market forecasts, access the full report at DelveInsight.

0 notes

crownbioscience · 1 year ago

Text

Tumor Microenvironment and Immuno-Oncology: Understanding the Interplay

Introduction

In the intricate landscape of cancer, the tumor microenvironment (TME) plays a pivotal role in shaping the immune response and influencing disease progression. This article explores the dynamic interplay between the tumor microenvironment and immuno-oncology, shedding light on the complexities that researchers and healthcare professionals navigate in the quest for more effective cancer treatments.

The Tumor Microenvironment Unveiled

The TME encompasses a complex milieu of cells, including cancer cells, immune cells, fibroblasts, and blood vessels, as well as signaling molecules. Understanding this ecosystem is crucial as it significantly impacts the success of immuno-oncology interventions.

Immune Cells in the Tumor Microenvironment

Immune cells within the TME can either promote or inhibit anti-tumor responses. T cells, for instance, are instrumental in recognizing and attacking cancer cells, while regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) can dampen immune responses, creating a challenging environment for effective immunotherapy.

Cytokines and Signaling Molecules

Cytokines and signaling molecules within the TME act as messengers, influencing the behavior of immune cells. Their intricate signaling networks can either enhance or suppress immune responses, directly impacting the efficacy of immuno-oncology treatments.

Immuno-Oncology Strategies Targeting the TME

Researchers are developing innovative immuno-oncology strategies that specifically target the TME. These include therapies aimed at modifying the TME to be more receptive to immune attack or inhibiting immunosuppressive signals, thereby unleashing the full potential of the immune system against cancer.

Challenges in the Tumor Microenvironment

The TME poses challenges for immuno-oncology treatments. Factors such as hypoxia, acidity, and the presence of immunosuppressive cells create a hostile environment that can undermine the effectiveness of immunotherapies. Recognizing and overcoming these challenges is critical for advancing treatment outcomes.

Biomarkers and Predictive Tools

Identifying biomarkers within the TME can serve as predictive tools for treatment response. Researchers are actively exploring molecular signatures that can guide clinicians in tailoring immuno-oncology interventions based on the unique characteristics of the TME.

Personalized Medicine and the TME

The concept of personalized medicine in immuno-oncology extends to understanding and targeting the unique features of the TME for each patient. This tailored approach aims to optimize treatment responses while minimizing potential side effects.

Clinical Trials and TME Research

Ongoing clinical trials focus on unraveling the complexities of the TME and testing novel immuno-oncology interventions. Participation in these trials is essential for advancing our understanding and refining treatment strategies.

Future Directions and Innovations

As the field of immuno-oncology evolves, researchers are exploring cutting-edge technologies and therapeutic approaches to further manipulate the TME. This includes precision medicine, gene therapies, and advanced imaging techniques to gain deeper insights into the TME's dynamics.

Collaborative Efforts in TME Research

The intricate interplay between the TME and immuno-oncology necessitates collaborative efforts among researchers, clinicians, and pharmaceutical companies. Sharing insights and data is crucial for accelerating breakthroughs in cancer treatment.

Conclusion

Understanding the interplay between the tumor microenvironment and immuno-oncology is paramount for advancing cancer therapies. As researchers continue to unravel the complexities of the TME, the potential for more effective and personalized immuno-oncology treatments becomes increasingly promising. This symbiotic relationship between science and clinical application holds the key to unlocking new frontiers in the fight against cancer.

1 note · View note

healthcaremarketfmi · 2 years ago

Text

Glioblastoma Treatment Drugs Market Future Trends Analysis, Business Insights, Manufacturing Cost Structure, Global Share Forecast to 2032

The global glioblastoma treatment drugs market is worth US$ 723.3 Mn as of now and is expected to reach US$ 1.26 Bn by the year 2032 at a CAGR of 5.7% between 2022 and 2032.

Patients have started getting clinical trials with development agents. Biomarkers are more successful regarding personalized medicine. There is a likelihood of tumor getting located in spinal cord, which does represent close to 15% of all sorts of primary brain tumors. This actually drives the demand pertaining to glioblastoma treatment drugs.

Drugs that are involved in the treatment of glioblastoma are antineoplastic cytotoxic drugs. This is amongst the remarkable developments in the chemotherapy drugs for treating malignant tumors. Every passing year sees an influx of new drugs for overcoming blood-brain barrier. Manufacturers are on the toes. In other words, they are into extensive research regarding upgradation of drugs to treat glioblastoma.

Variation in treatment approach of patient to patient resulting in tumor heterogeneity is actually expected to account for rise in demand for ‘personalized treatment approach’ for managing glioblastoma multiforme. New treatments are on the way, and expected to increase the life-span of the patients contracting glioblastoma multiforme. Along these lines, the US FDA, in July 2020, did grant ‘fast track designation’ to DB102 (enzastaurin) from Denovo Biopharma to treat the patients who are diagnosed with this disease.

Radiation therapy holds more than 30% of the market share due to enhanced rates of survival. Using temozolomide with radiotherapy does increase the tumor’s sensitivity to radiation. So, it’s advisable to avoid it.

It also needs to be considered that glioblastoma is aa complex disease, which says that its treatment does involve numerous approaches combining several treatments. Not all the economies have a good understanding of the ailment. As such, they can’t boast of efficient treatment. This would, in turn, be highly dependent on the investment being put in. It’s actually to wait and watch the entire thing. Future Market Insights has walked through these facts with future perspectives in its latest market study entitled ‘Glioblastoma Treatment Drugs Market’.

Key Takeaways from Glioblastoma Treatment Drugs Market

North America holds more than 30% of the market share and the status quo is expected to remain the same even in the forecast period. This could be credited to the US alone being home to18K people diagnosed with glioblastoma.

Europe holds the second-largest market share. It, in fact, contributes for 27% of the revenue. As of now, 25K cases have been reported till date. The UK is leading from the front.

The Asia-Pacific is expected to witness the fastest growth in glioblastoma treatment drugs market with benevolence amongst the population.

For more Information : https://www.futuremarketinsights.com/reports/glioblastoma-treatment-drugs-market

Competitive Landscape

Merck company, in 2019, completed acquisition of Peloton Therapeutics (a bio-therapeutic clinical-stage organization) for helping in treatment of brain cancer. A small molecule has been strongly developed for treating hypoxia-inducible factor- 2α (HIF-2α).

Lineage Cell Therapeutics inked a licensing deal with Immunomic Therapeutics in April 2021 to create allogeneic VAC cancer immunotherapy platform (used for treating glioblastoma multiform). As per the deal, Lineage received US$ 2 Mn payment upfront, along with US$ 67 Mn in the commercial milestone payments.

“Growing occurrences of brain tumors are likely to take the glioblastoma treatment drugs market by storm in the near future”, says an analyst from Future Market Insights.

What’s the enclosure with glioblastoma treatment drugs market?

Future Market Insights offers an exclusive perspective and various real-time insights on the glioblastoma treatment drugs market in its latest study, presenting historical demand assessment of 2016 – 2021 and projections for 2022 – 2032.

The research study is based on drug class (antineoplastic, VEGF/VEGFR inhibitors, alkylating agents, and miscellaneous antineoplastic), and by distribution channel (hospitals, cancer research organizations, long term care centers, and diagnostic centers).

With increasing incidences of cancer coupled with rising geriatric population, the global glioblastoma treatment drugs market is likely to grow in an aplomb in the near future.

0 notes

kritikarehani · 5 years ago

Photo

Hypoxia Epidemiology Insights 2030

According to a study, the incidence rates of Hypoxic Brain Injury are approximately 50 per 100,000 population and survival-to-discharge rates of roughly 8% which represents over 10,000 patients per year in the United States alone.

Source: https://www.delveinsight.com/report-store/hypoxia-market

#hypoxia market #hypoxia market share #hypoxia market size #hypoxia market trends #hypoxia market research reports #hypoxia key companies #hypoxia epidemiology analysis #hypoxia epidemiology

0 notes

eretzyisrael · 4 years ago

Text

Israeli researchers have developed a radioactive marker to detect small and aggressive cancerous tumors. The research on a hypoxia radioactive marker, which identifies oxygen-deficient cells, was developed by Isotopia Molecular Imaging Ltd., and led by Prof. Sharon Ruthstein from the Department of Chemistry at Bar-Ilan University.

Studies have shown that oxygen concentration in the cell is directly related to the aggressiveness of cancerous tumors. The hypoxia radioactive marker, which is based on the Copper 64 isotope, will not only determine if the tumor is malignant or benign, but also how aggressive it is through a single image, eliminating the need for a biopsy, the university’s BIRAD – Research and Development Company Ltd. said in a statement.

The probability of cure depends largely on the type of cancer tumor and the stage at which the disease is discovered. Accurate means of diagnosis in the early stages is key to saving lives, according to the statement.

#Israel #Cancer #Medical Treatment #Medical developments

10 notes · View notes

cricsart · 3 years ago

Link

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

0 notes

hknd123321 · 3 years ago

Text

YB1 innovative thrombolytic drug may change the treatment landscape

Cardiovascular disease is currently the largest cause of death in the world and one of the most common diseases in China, bringing a heavy burden to millions of families and society. Although my country has made great progress in the prevention and treatment of cardiovascular diseases, there are still many problems to be solved in a series of prevention and treatment processes, including prevention awareness, medical technology and new drug research and development.

In less than two months since the beginning of 2022, the sudden death of employees in major Internet companies has exploded the Internet, especially the protagonists who lost their lives in recent incidents are quite young, which is even more distressing to the world. Follow-up reports show that many young people are currently under great work and life pressure, and habits such as long-term overtime and staying up late seriously damage their health, and some people have symptoms such as angina pectoris, myocardial infarction and severe arrhythmia, which are all risk factors that may lead to sudden death.

Blood clots are the main culprit in many cardiovascular diseases

In 2020, there are about 330 million patients with cardiovascular disease in China, including more than 13 million stroke patients and more than 11 million coronary heart disease patients. Cardiovascular disease is the third largest treatment area in China in 2020, and there is a huge unmet medical need. satisfy.

According to public data, cardiovascular death, stroke and heart attack are the main causes of death and disability in my country. In 2020, more than 4.5 million patients in China will die due to cardiovascular disease, and the mortality rate is as high as 3.2‰, while the mortality rate of cancer in China is 1.6‰, and the mortality rate of cardiovascular disease in the United States is 2.17‰, which shows the severe development of cardiovascular disease in my country. situation.

As the top three fatal cardiovascular diseases in the world, myocardial infarction, stroke and venous thromboembolism all share a common pathogenesis, that is, thrombosis. Therefore, understanding thrombosis and its treatment methods is also of great significance for the prevention and treatment of cardiovascular diseases.

How do blood clots form?

A thrombus is a small mass formed by blood flow on the surface of a peeling or repairing part of the inner surface of a blood vessel in the cardiovascular system. In the variable fluid-dependent type, a thrombus consists of insoluble fibrin, deposited platelets, accumulated leukocytes, and trapped red blood cells . Thrombosis is a pathological process in which under certain conditions, formed blood components form emboli in blood vessels, resulting in partial or complete blockage of blood vessels and obstruction of blood flow in the corresponding parts.

The three recognized conditions of thrombosis are: endothelial cell damage, changes in blood flow and increased blood coagulation.

Thromboembolism is a pathological process in which the thrombus falls off from the formation site and partially or completely blocks some blood vessels in the process of moving with the blood flow, causing ischemia, hypoxia, necrosis or congestion and edema of the corresponding tissues and organs.

Diseases caused by thrombosis and thromboembolic processes are called thrombotic diseases. Thrombosis is also the "culprit" of serious cardiovascular diseases such as myocardial infarction, cerebral stroke and venous thromboembolism. Anti-thrombosis has also become the key to preventing and treating such cardiovascular diseases.

In fact, my country's cardiovascular disease drug market is quite mature, and generally shows a considerable degree of competition, but the competition in the innovative cardiovascular disease drug market is relatively limited.

For pharmaceutical companies to enter the field of cardiovascular disease treatment in China, many industry barriers need to be broken: Due to the complex pathology of cardiovascular disease, the development of innovative cardiovascular disease drugs faces high technical barriers; surrogate endpoints are not suitable for assessing clinical benefits in the field of cardiovascular disease. Therefore, the clinical trial process is quite time-consuming; and the research and development cycle of cardiovascular disease drugs is long, the clinical conversion efficiency is low, and the development capital investment is large.

In the cardiovascular disease drug market, antithrombotic drugs are drugs used for thrombosis prevention and thromboembolic disease treatment, which can reduce the formation of thrombus in arteries and veins and promote the dissolution of formed thrombus.

Overview of Antithrombotic Drug Market Development

At present, the sub-categories of antithrombotic drugs mainly include three categories: antiplatelet drugs, anticoagulant drugs, and thrombolytic drugs. Among them, antiplatelet drugs are mainly used for the treatment of inhibiting platelet aggregation, anticoagulants are used to prevent blood coagulation, and thrombolytic drugs are used to treat acute thromboembolic diseases. Among these three types of antithrombotic drugs, antiplatelet drugs currently account for the highest proportion of the relevant market in my country.

Specifically, the segmentation structure of my country's antithrombotic drug market is quite different. At present, the market demand for antiplatelet drugs is the highest, accounting for about 65%. At the same time, the market growth rate in recent years is about 6%; The ratio is about 24%, and the market growth rate has been about 9% in recent years; the market share of thrombolytic drugs is 11%, but the market growth rate has been around 30% in recent years.

In the global antithrombotic drug market, the market of anticoagulants and thrombolytic drugs is relatively high. According to the development experience of developed countries, the market share of domestic anticoagulants and thrombolytic drugs will continue to grow in the future, becoming the growth of the antithrombotic drug industry. the main driving force.

Affected by factors such as population aging and unhealthy eating habits, the number of patients with cardiovascular and cerebrovascular diseases in the world has gradually increased. With the rising prevalence of cardiovascular disease in my country in recent years, there is still huge demand and room for expansion in the antithrombotic drug market. In order to reduce the mortality rate of cardiovascular disease, my country's large pharmaceutical companies have entered the field of antithrombotic drugs to accelerate the development of the antithrombotic drug industry.

Relevant research reports from industry institutions show that the market demand for antithrombotic drugs in my country has continued to rise in recent years. In 2019, the sales of antithrombotic drugs in public hospitals in my country were about 34.5 billion yuan, an increase of 10% compared with the previous year. Driven by the implementation of policies and the growth of anticoagulant drugs and thrombolytic drugs, the overall market size of antithrombotic drugs is showing an increasing trend.

YB1 deploys innovative thrombolytic drug product pipeline and enters the field of cardiovascular disease treatment

In recent years, thrombolytic drugs, which have been ahead of the market growth rate, have gradually become a potential track that has attracted much attention from the industry. In fact, for the treatment of thrombotic diseases in the cardiovascular field, the availability of thrombolytic drug therapy has been continuously improved in recent years, and it has become more and more common in clinical applications.

According to industry report data, the market size of China's thrombolytic drugs in 2019 is about 2.004 billion yuan. Among them, the largest single product of thrombolytic drug in my country is alteplase (rt-PA), accounting for about 70.23% of the market size of thrombolytic drugs in China, with a sales scale of about 1.407 billion yuan; the second largest type of thrombolytic drug is urokinase , accounting for about 14.67% of China's thrombolytic drug market size, with a sales scale of about 294 million yuan; while the core product of the thrombolytic track industry giant Tasly, Puyoke, is the third largest thrombolytic drug product in China, accounting for about 294 million of China's thrombolytic drug products. 12.24% of the drug market size.

It is reported that Puyoke is only approved for the indication of acute ST-segment elevation myocardial infarction. Compared with alteplase and urokinase, Puyoke has a relatively single indication range, so the overall market share is small. However, with the approval of Puyoke's new indications in the future, its market share is expected to expand further.

However, the two commonly used thrombolytic drugs recombinant urokinase and rt-PA have short half-lives of only 4-8 minutes, which cannot relieve the onset of acute thrombosis. The innovation and iteration of drugs has become inevitable.

As an innovative biopharmaceutical company, the biomacromolecule drug delivery carrier YB1 developed by Hong Kong Medicine Oncolysis can release thrombolytic agents at the location of thrombosis, avoiding the problems caused by excessive thrombolysis, and has recently attracted widespread attention in the industry market.

The company's core technology product, YB1, adopts the world's first thrombus targeting technology, and can be combined with a variety of thrombolytic drugs to precisely target thrombus to release thrombolytic drugs, and play a precise role in targeted thrombolysis. This emerging thrombolytic therapy technology is currently in The field of antithrombotic drug research and development is a very fresh and cutting-edge attempt, and the prospect is worth looking forward to.

In terms of specific drug pipelines, YB1-rt-PA is the first-generation fixed-point thrombus ablation product deployed by the company.

In addition, Hong Kong Medicine Oncolytic has also deployed two product pipelines, YB1-rt-DE and YB1-rt-PL, which combine YB1 with defibrase and plasmin. We look forward to the final maturity of this new technology, which will serve the thrombolytic therapy market. Bring more surprises.

0 notes

jesse-pinkman123 · 3 years ago

Text

Post-operative Pain Management Market Repository Of Analysis And Information For Every Facet Of The Market

Global Post-operative Pain Management Market

Post-operative pain includes all types of acute pain that occur due to injuries and resolve in an appropriate healing period. Such pain often responds to analgesic medication, as well as a treatment of the precipitating cause. Post-operative pain could also trigger cardiovascular, respiratory, endocrine, metabolic dysfunctions. Post-operative pain treatment is thus aimed at mobilizing the patient as early as possible. It allows the patient to drink and eat and to be able to deep breathe and cough. If the patients are not made to undergo a proper post-operative pain treatment, they can potentially develop cardiac problems, chest infections, depression, wound-induced infection, and hypoxia. Post-operative pain treatment has evolved over recent years, with different concepts of how drugs affect the body when used in specific combinations.

Opioids and non-steroidal anti-inflammatory drugs are expected to contribute to a major market share, in terms of value, in the global post-operative pain management market. Opioids are substances that act on the opioid receptors to produce morphine-like effects. They are most often used to relieve pain. Whereas, non-steroidal anti-inflammatory drugs are used to treat pain, inflammation, and fever.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/154

Prevalent Scenario of the post-operative pain management market

Increasing number of surgical procedure is expected to act as a value-driver to the global postoperative pain management market. As per the World Bank, in the U.S. there were 30,537 number of surgical procedures performed in 2012. As per National Center for Health Statistics, of overall surgical procedures half of the procedure requires postoperative pain medication which provides high opportunity for manufacturers. As per Centers for Disease Control and Prevention (CDC), every year there are around 41 million visits in emergency department due to trauma. Around 450,000 burns require medical attention annually. Increase in trauma cases to act as a fuel to the overall growth of postoperative pain management market. Some postoperative pain drugs include side effects. Despite the many advancement in postoperative pain management, opioids are still considered as the mainstay pain therapy in many settings. All opioids have significant side effects that are limiting its use. One of the major side-effects associated with the use of opioid is respiratory depression. According to CDC, the prescription opioid overdose killed around 16,500 people in 2015. The increasing cases of drug overdoses and side-effects associated with postoperative pain drugs is expected to act as a restraint to the overall market. Increasing geriatric population in emerging economies and increasing prevalent cases of acute diseases is expected to fuel growth of the market. Increasing patient awareness regarding surgeries and operations and the growing research related to pain management is expected to create high opportunity for pain relieving drug manufacturers. Increasing government’s initiative to promote better postoperative pain treatment is expected to increase growth of market. One such initiative is APOP project (Acute postoperative pain management), it is national multicenter quality improvement initiative started by Australia government in 2008. The project was aimed to improve the management of postoperative pain by promoting the best practice. North America region is expected to contribute major share to the overall postoperative pain management market due to the increasing healthcare expenditure, better reimbursement policies, easy availability of advanced healthcare treatment and growing healthcare infrastructure in these region. Europe is expected to be the second most lucrative market for the postoperative pain management.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/postoperative-pain-management-market-154

Global Post-operative Pain Management Market – Key Players

The global postoperative pain management market is highly fragmented, owing to the participation of many established and emerging players, such as Bayer AG, DURECT Corporation, Pfizer Inc., BTG International Ltd, Novartis AG, and A.P. Pharma, Inc.

Key Developments

These market contenders are involved in various business strategies, such as gaining product approval from regulatory authorities, in order to strengthen their market presence. For instance, in July 2019, Alembic Pharmaceuticals, a leading India-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for pregabalin capsules, which are indicated for neuropathic pain. In July 2019, InvaGen Pharmaceuticals, a subsidiary company of Cipla Limited, received the FDA approval for its generic version of pregabalin capsules. These capsules are indicated for the management of neuropathic pain associated with certain diseases. Furthermore, BioElectronics Corporation received the U.S. FDA approval for its RecoveryRX device, which is indicated for treatment of post-operative pain, in August 2019.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/154

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

mailto:[email protected]

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

#Post-operative Pain Management Market Outlook #Post-operative Pain Management Market Growth

0 notes

updatemarketanalysisreport · 4 years ago

Text

Hemodynamic Monitoring Market: Future Scope, Size, Business Growth, Industry Top Companies Share, Outlook, and Forecast

According to the latest report by IMARC Group, titled “Hemodynamic Monitoring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the global hemodynamic monitoring market size exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the global hemodynamic monitoring market to grow at a CAGR of 7% during 2021-2026. Hemodynamic monitoring systems help in measuring the blood pressure in the veins, heart and arteries. They also record the blood flow rate and the amount of oxygen present in the blood. They are primarily used for clinical inspection of cardiovascular health, longevity and quality of life of patients undergoing and recovering from cardiac surgery. As several treatments rely on the observation of small changes that take place inside the human heart, the demand for hemodynamic systems is escalating across the globe.

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviors of the consumers globally-our estimates about the latest market trends and forecast values after considering the impact of this pandemic. These observations will be integrated into the report.

Request Free Sample Report: https://www.imarcgroup.com/hemodynamic-monitoring-market/requestsample

Global Hemodynamic Monitoring Market Trends:

Hemodynamic monitoring systems are employed in the healthcare sector for combating tissue hypoxia, shock and multiorgan failure in critically ill patients. This, in confluence with the increasing number of individuals suffering from cardiac dysfunction, represents one of the significant factors strengthening the market growth. Additionally, due to the growing geriatric population, government and non-government organizations are undertaking various initiatives to decrease healthcare costs, which in turn is bolstering the hemodynamic monitoring market growth. Furthermore, some of the leading players in the industry are increasing their budget to invest in research and development (R&D) activities. They are also undertaking initiatives for introducing simple minimally- and non-invasive hemodynamic monitoring systems at affordable prices.

Ask Customization and Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/hemodynamic-monitoring-market

Key Market Segmentation:

Competitive Landscape with Key Player:

Edwards Lifesciences Corporation

LiDCO Group Plc

Deltex Medical Plc

Pulsion Medical Systems SE

General Electric Company

Osypka Medical GmbH

Baxter International Inc.

Tensys Medical Inc.

ICU Medical Inc.

Argon Medical Devices Inc.

Schwarzer Cardiotek GmbH.

Market Breakup by Product:

Disposables

Monitors

Others

Market Breakup by Monitoring Type:

Invasive Monitoring

Minimally Invasive Monitoring

Noninvasive Monitoring

Market Breakup by End-User:

Hospitals

Clinics and Ambulatory Care Centers

Home Care Settings

Others

Market Breakup by Region:

North America

Asia Pacific

Europe

Latin America

The Middle East and Africa.

Key Highlights of the Report:

Market Performance (2015-2020)

Market Outlook (2021- 2026)

Porter’s Five Forces Analysis

Market Drivers and Success Factors

SWOT Analysis

Value Chain

Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Related Report:

Luxury Travel Market: https://www.imarcgroup.com/luxury-travel-market

Optical Imaging System Market: https://www.imarcgroup.com/global-optical-imaging-system

Coronavirus Precautionary Products Market: https://www.imarcgroup.com/coronavirus-precautionary-products-market

Premium Denim Jeans Market: https://www.imarcgroup.com/premium-denim-jeans-market

Cogeneration Equipment Market: https://www.imarcgroup.com/cogeneration-equipment-market

Polycaprolactone Market: https://www.imarcgroup.com/polycaprolactone-market

United States E-Cigarette Market: https://www.imarcgroup.com/united-states-cigarette-market

Soft Tissue Repair Market: https://www.imarcgroup.com/soft-tissue-repair-market

Metal Powder Market: https://www.imarcgroup.com/metal-powder-market

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us: IMARC Group 30 N Gould St, Ste R Sheridan, WY (Wyoming) 82801 USA Email: [email protected] Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

0 notes

healthcaremarketfmi · 2 years ago

Text

Glioblastoma Treatment Drugs Market Industry Analysis Report, Country Outlook, Application Potential, Forecast 2022 to 2032

The global glioblastoma treatment drugs market is worth US$ 723.3 Mn as of now and is expected to reach US$ 1.26 Bn by the year 2032 at a CAGR of 5.7% between 2022 and 2032.

Key Takeaways from Glioblastoma Treatment Drugs Market

Europe holds the second-largest market share. It, in fact, contributes for 27% of the revenue. As of now, 25K cases have been reported till date. The UK is leading from the front.

The Asia-Pacific is expected to witness the fastest growth in glioblastoma treatment drugs market with benevolence amongst the population.

For More Information: https://www.futuremarketinsights.com/reports/glioblastoma-treatment-drugs-market

Competitive Landscape

“Growing occurrences of brain tumors are likely to take the glioblastoma treatment drugs market by storm in the near future”, says an analyst from Future Market Insights.

What’s the enclosure with glioblastoma treatment drugs market?

With increasing incidences of cancer coupled with rising geriatric population, the global glioblastoma treatment drugs market is likely to grow in an aplomb in the near future.

0 notes

kritikarehani · 5 years ago

Text

Hypoxia Market Insights, Epidemiology and Market Forecast 2030

Hypoxia is a state in which oxygen is not available in sufficient amounts at tissue level to maintain adequate homeostasis; this can result from inadequate oxygen delivery to the tissues either due to low blood supply or low oxygen content in blood (hypoxemia).

DelveInsight's "Hypoxia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hypoxia , historical and forecasted epidemiology as well as the Hypoxia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hypoxia market report provides current treatment practices, emerging drugs, Hypoxia market share of the individual therapies, current and forecasted Hypoxia market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hypoxia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

· The United States

· EU5 (Germany, France, Italy, Spain, and the United Kingdom)

· Japan

Study Period: 2017-2030

Hypoxia Disease Understanding and Treatment Algorithm

Hypoxia can vary in intensity from mild to severe and can present in acute, chronic, or acute and chronic forms. The response to hypoxia is variable; while some tissues can tolerate some forms of for a longer duration, other tissues are severely damaged by low oxygen levels. Hypoxia/ ischemia

Cerebral hypoxia refers to a situation in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow, it affects the largest parts of the brain, called the cerebral hemispheres.

The DelveInsight Hypoxia market report gives a thorough understanding of the Hypoxia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Hypoxia.

Treatment

It covers the details of conventional and current medical therapies available in the Hypoxia market for the treatment of the condition. It also provides Hypoxia treatment algorithms and guidelines in the United States, Europe, and Japan.

Request for sample pages: https://www.delveinsight.com/sample-request/hypoxia-market

Hypoxia Epidemiology

As per a study:

• Stroke is the third leading cause of death in the United States. More than 140,000 people die each year from stroke in the United States.

• Every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes.

• About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked

The Hypoxia epidemiology division provide insights about historical and current Hypoxia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hypoxia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hypoxia Epidemiology

The epidemiology segment also provides the Hypoxia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hypoxia Drug Chapters

The current pipeline for Hypoxia has many significant products. The dynamics of Hypoxia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also due to the expected launch of many therapies during the forecast period.

Drug chapter segment of the Hypoxia report encloses the detailed analysis of Hypoxia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hypoxia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Hypoxia treatment.

Hypoxia Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Hypoxia treatment.

Request access to free sample pages: https://www.delveinsight.com/sample-request/hypoxia-market

Hypoxia Market Outlook

Treatment of vascular brain disorders has great impact clinically, financially, and socially throughout the world. Prevention of their occurrence through lifestyle adjustments and clinical antihypertensive treatment is an essential part of the therapy to reduce stroke probability and vascular malfunction-related gradual decline in memory.

Treatment depends on the underlying cause of the hypoxia, the most important treatment for cerebral hypoxia involves removing the source of the oxygen deprivation, along with extensive physical, occupational, or speech therapy to teach brain how to work around any damaged areas. Such therapy can be challenging and emotionally draining, but the more committed treatment approaches.

Management of hypoxia falls under 3 categories: maintaining patent airways, increasing the oxygen content of the inspired air, and improving the diffusion capacity

Some other treatments include drugs to prevent future hypoxia episodes; this may include the use of blood thinners, antibiotics to treat infections that caused or resulted from the hypoxia, surgery to remove any blockages or to discover the source of the blockage. Also, it is supported by the use of assistive gear, such as a wheelchair, psychotherapy and basic life-support systems (mechanical ventilation to secure the airway; fluids, blood products, or medications to support blood pressure and heart rate; and medications to suppress seizures).

To meet the current unmet needs of the Hypoxia market, companies like Diffusion Pharmaceuticals, Biogen and many others are developing therapies for the treatment of this indication.

The factors that shall expedite the growth of Hypoxia market include increasing awareness about available treatments during the forecast period (2019–2030). Overall, the increasing Incidence, disease awareness, and promising emerging pipeline therapies will propel the market size forward during the forecast period. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hypoxia.

The Hypoxia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Hypoxia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Hypoxia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Hypoxia market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Hypoxia market in 7MM.

The United States Market Outlook

This section provides the total Hypoxia market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Hypoxia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Hypoxia market size and market size by therapies in Japan is also mentioned.

Download sample pages of the report @ https://www.delveinsight.com/sample-request/hypoxia-market

View a detailed report on Hypoxia: https://www.delveinsight.com/report-store/hypoxia-market

#hypoxia market #hypoxia market share #hypoxia market size #hypoxia market trends #hypoxia market research reports #hypoxia epidemiology #hypoxia key companies

0 notes

sandlerresearch · 4 years ago

Text

Chronic Kidney Disease Anemia - Global Drug Forecast and Market Analysis to 2029 published on

https://www.sandlerresearch.org/chronic-kidney-disease-anemia-global-drug-forecast-and-market-analysis-to-2029.html

Chronic Kidney Disease Anemia - Global Drug Forecast and Market Analysis to 2029

Chronic Kidney Disease Anemia – Global Drug Forecast and Market Analysis to 2029

Summary

Anemia is a common complication of chronic kidney disease (CKD) that is most frequently attributed to insufficient synthesis of erythropoietin (EPO) due to kidney damage. CKD anemia is highly prevalent among CKD patients and its prevalence increases as CKD progresses, affecting more than half of patients in stage V. Over the last 20 years, the CKD anemia market has grown exponentially. Treatment of CKD anemia was significantly improved following the introduction of recombinant human EPO (rHuEPO), and ESAs have dominated the disease space as the standard of care.

The CKD anemia market is relatively well-established; many physicians believe that the existing therapies, namely ESAs, effectively control anemia for most patients. However, despite several options, there is still room for improvement and innovation within the space. GlobalData has identified a variety of unmet needs. While ESAs have improved the treatment for patients with CKD anemia, their safety profiles are not ideal. As injectable ESAs often stimulate EPO to supraphysiologic levels, which subsequently associates their use with increased cardiovascular (CV) risks, safer treatment options for CKD anemia is currently the most significant unmet need for the condition.

Major drivers of growth in the CKD anemia market over the forecast period include: the launch and uptake of novel hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) drug class across all markets covered in the report will drive the growth of the CKD anemia market. GlobalData expects this novel class of drugs, which includes several recently approved and late-stage candidates, to have steady uptake across the 8MM, as they are anticipated to address some of the main unmet needs in the space. Market growth will also be driven by the launch of several oral and IV iron products in addition markets.

GlobalData expects the market to increase to $6.6B in 2029 at a Compound Annual Growth Rate (CAGR) of 3.4%. Furthermore, the China CKD anemia market is expected to experience the highest growth, increasing to $962M (14.6% of global market share) by 2029, at a CAGR of 9.9%. Sales in the other regions are also expected to increase by the end of the forecast period. This global growth is driven mainly by the anticipated approval and launch of HIF-PHIs but will likely be tempered by marked biosimilar erosion of several top-selling currently marketed branded erythropoiesis-stimulating agents (ESAs).

Key Highlights

– Despite therapies currently available to anemia in CKD patients, there is still room for improvement within the space. Global sentiment among KOLs included the growing need for safer treatment options, less burdensome drug administration, and the importance of novel therapies for patients resistant to ESA treatment. – Although ESAs are forecast to remain the highest-grossing drug class at the end of the forecast period, this drug class has a negative CAGR of 2.9%. This decline in sales can be largely attributed the launch of HIF-PHIs and biosimilar competition. – These market dynamics will occur against a backdrop of a moderate growth of global CKD anemia prevalent cases over the 10-year forecast period, with approximately 2.6 million drug treated cases across the 8MM in 2029.

KEY QUESTIONS ANSWERED

– Despite the existence well-established treatment options for treating CKD anemia, a fewyet significantunmet needs remain. – Which unmet needs are the most pressing in the 8MM? – Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space? – Sales in the CKD anemia market are dominated by the highly lucrative ESA class of drugs – What factors will shape the competitive treatment landscape? – Will ESAs maintain their strong market position? – How much pressure will they face from new entrants?

Several HIF-PHIs have recently been marketed or are soon expected to gain their first approval among the 8MM – – Which companies are leading the way with their own HIF-PHI? – What do KOLs say about their clinical and commercial positioning? – How are they expected to shape the future CKD anemia treatment paradigm?

Scope

– Overview of CKD anemia including epidemiology, disease etiology and management. – Topline CKD anemia drugs market revenue (including ESAs and iron therapies), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs. – Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5U, Japan and China over the 10-year forecast period. – Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. – Analysis of the current and future market competition in the global angina pectoris therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Reasons to Buy

The report will enable you to – – Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines. – Develop business strategies by understanding the trends shaping and driving the global angina pectoris therapeutics market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global angina pectoris market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Track drug sales in the global CKD anemia therapeutics market from 2019-2029. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

#Pharmaceutical

0 notes

pratikkadbane · 4 years ago

Text

Global Oxygen Therapy Device Market, by Types (Non-re-breather mask, Incubators, Continuous positive airway pressure, Liquid oxygen device, Hyperbaric oxygen chamber, Nassal cannula, Cylinder, Concentrators and Oximeter); by Application (Hypoxaemia, Heart diseases, Sleeping apnea, Lung diseases, Chronic obstructive pulmonary diseases, Respiratory issues and others) and by End Users (Hospital, Clinics, Patients) - Forecast to 2023

The global market of Oxygen therapy device is expected to grow at approximate 12% CAGR. The market is expected to reach USD 15 billion by 2023 as compared to 8 billion in 2016. Oxygen is required by cells to do work. Oxygen therapy is required for the supplement of oxygen in body through external mean to the people who have respiratory disorder. The oxygen therapy is much required by the people who have chronic obstructive pulmonary diseases (COPD) for long term use.

The levels of oxygen are checked by the oximeter, which checks levels indirectly. The oximeter is a small device which gets clipped into person’s body parts. The levels are checked before giving oxygen therapy so that doctors gets an idea whether patients will get benefited with the oxygen therapy. If the person is found with the low levels of oxygen then he/she can be the one applicant for the oxygen therapy.

Generally, the patients of Asthma, Heart diseases, Sleeping apnea, lung diseases, COPD and other respiratory issues can get benefited from the oxygen therapy as it enhances the breathing power and patient can stay more active for long. The symptoms like weakness, headaches, fatigue, irritability and more will be reduced. The oxygen therapy is also helpful for the children with chronic lung conditions.

The global market of oxygen therapy device is growing fast because of the rising prevalence of lung, respiratory, heart and other diseases. The number is growing across the world because of the changing lifestyle.

Key Players for Oxygen therapy Market:

There are various local and global players who manufacture the devices for oxygen therapy. Some of them are Phillips healthcare, Devilbiss Healthacre, Cardinal Healthcare, Respironics, Salter Labs, Masimo Corporation, Carefusion, Teflex, Bio Med, Fisher & Paykel Healthcare Limited, Inogen, O2 Concepts, Smith medicals, Medtronic, 3B Medical, 3M Healthcare and many more.

Intended Audience

Oxygen system manufacturers

Oxygen system Suppliers

Bio-supplier companies

Research and Development (R&D) Companies

Medical Research Laboratories

Academic Medical Institutes and Universities

Market Segments:

The oxygen therapy device market is segmented by the types of products (Non-re-breather mask, Incubators, Continuous positive airway pressure, Liquid oxygen device, Hyperbaric oxygen chamber, Nassal cannula, Cylinder, Concentrators and Oximeter), application (Hypoxia, Heart diseases, Sleeping apnea, Lung diseases, Chronic obstructive pulmonary diseases, Respiratory issues and others) and by end users (Hospital, Clinics, Patients). Oxygen Therapy Device Market Share by Application Type, 2016 (%)

Regional Analysis of Oxygen Therapy Device Market:

Globally, America is the largest market for Oxygen therapy device market. America accounts for the major market of oxygen therapy device, it is nearly about 45%. Europe is the second largest regions which accounts for the maximum use of the oxygen therapy device. Asia-Pacific is the fastest upcoming and growing market and it is expected to grow by 8% CAGR in the coming years. The countries like India and China are accepting the oxygen therapy device as a home based solution.

Study Objectives of Oxygen Therapy Device Market:

To give detailed analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Oxygen therapy device market

To provide insights about factors affecting the market growth

To analyze the Oxygen Therapy Device market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries - Americas, Europe, Asia-Pacific, and Rest of the world.

To provide country level analysis of the market with respect to the current market size and future prospective

To provide country level analysis of the market for segments by type, by end users and its sub-segments

To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Oxygen therapy Device market.

The report for Global Oxygen Therapy Device Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

0 notes

jesse-pinkman123 · 4 years ago

Text

Europe Heparin Market To Reach US$ 4,085.8 Million By 2027 - Coherent Market Insights

Heparin is given parenterally and unfractionated heparin (UFH) has a half-life of about one to two hours after infusion. The half-life of low-molecular-weight heparin (LMWH) is about four to eight hours. Heparin is obtained naturally from mucosal tissues of slaughtered meat animals such as porcine intestines or bovine lungs or prepared synthetically.

Statistics:

Europe Heparin Market is estimated to account for US$ 4,085.8 Mn in terms of value by the end of 2027.

Europe Heparin Market: Drivers

Increasing prevalence of venous thromboembolism (VTE) is expected to propel growth of Europe heparin market over the forecast period. For instance, according to NHS Scotland’s 2018 report, 75,846 people were admitted to hospital for VTE in Scotland from 2008 to 2017.

Europe Heparin Market: Opportunities

Potential of LMWH in reducing lung injury is expected to offer lucrative growth opportunities for players in Europe heparin market. For instance, in April 2020, researchers from Chang Gung Memorial Hospital, Taiwan, reported that LMWH reduced ventilation-induced lung injury through hypoxia inducible factor-1α in a murine endotoxemia model.

Europe Heparin Market: Restraints

Risk of heparin induced thrombocytopenia is expected to hinder growth of the market. Heparin-induced thrombocytopenia (HIT) is a complication of heparin therapy. There are two types of HIT: type 1 and type 2. Type 1 HIT occurs within two days of heparin therapy, while type 2 is observed within 4 days to 10 days of heparin therapy.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3960

Key Takeaways:

Europe heparin market was valued at US$ 2,698.7 Mn in 2019 and is forecast to reach a value of US$ 4,085.8 Mn by 2027 at a CAGR of 6.1% between 2020 and 2027. Increasing prevalence of venous thromboembolism (VTE) is expected to propel growth of Europe heparin market over the forecast period

Low Molecular Weight Heparin segment held dominant position in Europe heparin market in 2019, accounting for 81.4% share in terms of value, followed by Ultra Low Molecular Weight Heparin. Increasing demand for Low Molecular Weight Heparin in reducing lung injury is expected to drive the market growth.

Market Trends

Increasing prevalence of chronic kidney disease is boosting growth of the market. For instance, according to the study, ‘Prevalence and deaths for chronic kidney disease in 2017, and percentage change of age-standardized rates by location, 1990–2017’ published in February 2020, U.K. recorded around 5,636,676 cases of chronic kidney disease in 2017.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/europe-heparin-market-3960

Major players in the market are sourcing active pharmaceutical ingredients from Europe. For instance, in November 2019, Fresenius Kabi launched preservative-free Heparin Sodium Injection, USP in 5,000 USP units per 0.5 mL in Simplist ready-to-administer prefilled syringes, in the U.S. The drug’s active pharmaceutical ingredient is sourced from Europe.

Europe Heparin Market: Competitive Landscape

Major players operating in Europe heparin market include, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.

Europe Heparin Market: Key Developments

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in September 2019, Nichi-Iko Pharmaceutical, the parent company of Sagent Pharmaceuticals, Inc., collaborated with Eisai Co., Ltd. for the generic pharmaceutical business in China.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3960

About Coherent Market Insights:

mailto:[email protected]

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

#Europe Heparin Market Growth #Europe Heparin Market

0 notes

mukongs · 3 years ago

Text

Oncolytic bacterial immunotherapy has been added to cancer treatment

Cancer treatment is a long-term cause for human beings all over the world. In the face of rising morbidity and mortality, traditional surgery, chemotherapy or radiotherapy can no longer meet the rising demand for anti-cancer.

In recent years, tumor targeted therapy technology, which can achieve the purpose of local extermination by precisely guiding the tumor area and minimizing the damage of surrounding normal tissues, plays an increasingly important role in tumor therapy due to its specificity and targeting, and is becoming the main direction of tumor therapy.

In the field of targeted therapy, the discovery of ideal targets is the root of the development possibility of all new technology therapies. In the study of human solid tumors, scientists have found an excellent target for cancer treatment -- the hypoxic solid tumor microenvironment! This has laid a key foundation for the development and application of many new cancer treatment technologies, including the cutting-edge oncolytic bacterial immunotherapy technology.

Characteristics of solid tumor microenvironment

More than 90% of human tumors are solid tumors, including lung cancer, breast cancer, colon cancer, soft tissue sarcoma, etc. Scientific studies have found that the microenvironment of solid tumors is unique and abnormal. The basic structure of the tumor microenvironment can be roughly divided into three layers: in the circumference of blood vessels, the central layer is fully oxygenated and provides nutrients, enabling cancer cells to accumulate around abnormal blood vessels of tumors; Outside are hypoxic regions containing hypoxic cancer cells; Further out is the necrotic area of the tumor, which has no living cells.

Thus, solid tumors can be distinguished from surrounding normal tissue. The main differences between the two are the characteristics of the cancer cells and the formation of the tumor vasculature, which leads to the formation of areas of hypoxia and necrosis. Due to the inefficiency of vascular network replenishment, solid tumors will have areas of hypoxia and necrosis, where nutrient and oxygen levels are low.

Oxygen levels can vary in different environments. In air, about 21% (150 mm hg) and in mammalian tissues and organs, between 2% and 9% (15-70 mm hg). In the hypoxic regions of most tumors, oxygen levels are approximately below 0.7% (5 mm hg) and below 0.02% under certain severe hypoxic conditions.

Therefore, hypoxia is an ideal target for cancer targeted therapy.

How do bacteria target tumors?

Studies have found that some obligate anaerobe and facultative anaerobe can infiltrate through peripheral blood circulation and preferentially accumulate and proliferate in tumor, that is, have tumor targeting.

The reason may be related to the special microenvironment of tumor: Firstly, the rapid growth of tumor tissue will lead to insufficient blood supply in some areas of tumor, thus forming anaerobic and necrotic areas. It is these anoxic environments that provide a place for bacteria to gather and grow. Secondly, in order to satisfy the growth of tumor tissue, cells in tumor microenvironment will secrete angiogenic factors and reduce the release of angiogenic inhibitors, thus promoting the generation of blood vessels in tumor. However, the blood vessels in tumors are pathologic neovascularization, and their vascular network is deficient in structure and function. They may break, block and branch excessively. Abnormal vascular network is also an important reason for the occurrence of anaerobic zones in tumors. It is for this reason that the researchers speculate that the bacteria target the tumor tissue through gaps in the network of abnormal blood vessels.

In addition, the hypoxic microenvironment in the tumor can cause local deficiency of the immune system, resulting in a greatly reduced ability of the immune system to remove bacteria from the tumor. The tumor tissue with high metabolism and apoptotic cell fragments in necrotic area provide abundant raw materials for bacterial reproduction. These factors allow certain bacteria to exhibit specific tumor-targeting properties.

The role of the immune system in bacteria targeting tumors

In the tumor microenvironment, immune disorder is an important reason for tumor to escape immune monitoring. Recent studies have shown that tumor-infiltrating immune cells (such as macrophages) do not play an anti-tumor role, but promote tumor growth and increase its ability to invade and metastasize. The tumor microenvironment belongs to a chronic inflammatory environment. It has been said that the tumor itself is a wound that will never heal, because there are always a large number of immunosuppressive factors and growth factors such as GM-CSF, IL-6,10,13, VEGF, TGF-β and so on in this environment. These environments eventually lead to dysfunction of immune surveillance.

However, when the human body is infected by bacteria, the bacteria themselves will strongly stimulate the host's immune response. When the bacteria target the tumor, they tip the balance of immunosuppression in the tumor microenvironment. Studies have shown that when bacteria infect tumors, not only do the bacteria activate the neutrophils intensely, but they also introduce this antagonism into the anaerobic areas of the tumor, creating a long-term confrontation.

Saccheri et al. found that bacterial invasion of tumor cells results in a large presentation of tumor-specific antigens. This antigen is delivered directly to dendritic cells (DCs), causing a tumor-specific immune response. Therefore, it is of great significance to study the interaction between bacteria and immune system in the process of tumor infection, which will provide evidence and basis for tumor immunotherapy in the future.

The discovery of salmonella, which targets tumors, and the discovery of oncolytic bacteria have added to the list of cancer treatments

At present, with the rapid development of molecular biology and genetic engineering technology, more and more bacteria have been applied in the field of cancer treatment, including obligate anaerobe Clostridium, probiotic Bifidobacterium, listeria and so on. Among them, gram-negative facultative anaerobe Salmonella typhimurium has the most extensive application prospect.

Previous studies have shown that attenuated salmonella typhimurium can colonize tumor tissue 1,000 to 10,000 times more effectively than normal tissue, but subsequent investigations have shown that any modification of salmonella weakens not only its virulence, It also makes it less effective against tumors.

And because salmonella tends to accumulate in the liver and spleen, residual salmonella can cause a lot of damage if not removed quickly. In addition, because any single tumor treatment has its drawbacks, combination therapy is especially important, but previous studies have failed to highlight the advantages of Salmonella as a delivery warhead.

In 2011, the R&D team of Hong Kong Pharmaceutical Oncology Biopharmaceutical Co., Ltd. realized the efficient programming technology of Salmonella lambda-RED for the first time in the research, establishing the transformation foundation of salmonella synthetic biology. After more than a decade of development, the company created a genetically engineered strain of Salmonella Typhimurium, which it named YB1. The modified version of salmonella, known as YB1, is the world's first carrier of an oncolytic bacterium, marking a crucial technological breakthrough for the idea of using bacteria to treat cancer.

It is reported that Hong Kong Pharmaceutical Oncolytic Biopharmaceutical Co., Ltd. has been focusing on innovative drug research and development in the field of tumor targeted therapy, oncolytic bacteria YB1 is its current primary core technology products, the company is currently promoting the application of YB1 oncolytic bacteria immunotherapy technology in human clinical trials, and has laid out a number of product pipelines. But it should still be some time before its first anticancer drug hits the market.

Although no oncolytic bacteria products in the real sense have been approved for marketing in the world at present, major pharmaceutical companies around the world have begun to enter the layout of oncolytic bacteria track, and have achieved good response in the industry market recently. The field of tumor immunotherapy may soon usher in the spring of oncolytic bacteria therapy.

0 notes